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Section 6:
Research Trends

Celebrating Rare
Disease Day –
A look into Rare
Disease research
Iris Kisjes, MBA

28th February is Rare Disease Day, which
is an international advocacy day to help
raise awareness with the public about rare
diseases, the challenges encountered by
those affected, the importance of research to
develop diagnostics and treatments, and the
impact of these diseases on patients’ lives.
Rare Disease Day was first observed in
Europe in 2008. It was established by
EURORDIS, the European Rare Disease
Organization. In 2009, NORD partnered with
EURORDIS in this initiative and sponsored
Rare Disease Day in the United States. Since
then, the concept has continued to expand
beyond the US and Europe. In 2013, more
than 70 countries participated.

Country/Region/
Institute

Publications

Worldwide

5,879

Europe

2,679

United States

905

Germany

518

France

495

Université Paris 5

77

Harvard University

61

University of Munich

45
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Rare diseases collectively affect millions
of people of all ages globally, of which
approximately 18-25 million Americans. They
are often serious and life altering; many are
life threatening or fatal. In Europe a disease
is considered rare when it affects no more
than 5 individuals among 10,000 persons,
whereas the US considers a disease to
be rare when it affects less than 200,000
Americans. Since each of the roughly 7000
rare diseases affect only a relatively small
population, it can be challenging to develop
drugs and medical devices to prevent,
diagnose, and treat these conditions. In
general there is a lack of understanding of
the underlying molecular mechanisms or
even the cause or of many rare diseases.
Hence, countries across the globe should
share experiences and work together to help
address these challenges successfully.

SciVal is a ready-to-use tool to analyze
the world of research. It is based on
Scopus data and primarily developed for
research organizations to help establish,
execute and evaluate their strategies
within the context of their peers (through
benchmarking) and collaborators
(through collaboration networks). The
solution also allows users to set up
research areas to analyze contributors
within the field and their corresponding
publication and citation statistics.

Table 1: Scholarly Output for ‘Rare Disease’
research in 2009-2013 at different levels.
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The keyword search searches through titles,
abstracts and keywords of research papers
within Scopus.
Setting up a research area in SciVal is fairly
simple and can be completed in three easy
steps. Figure 1 shows that for this search
query a set of 12,818 publications were
published between 1996 to present, where
the US, Germany, Japan and France were the
most prolific.
The SciVal research area focuses its analysis
on the last five years of publications for which
we found the pool of research papers in this
area was is fairly small. Over the course of 5
years (2009-2013) close to 5900 publications
containing ‘rare disease’ were published
around the globe, of which less than 20%
originated from the US, see Table 1 (data date
stamp 21 January 2014).

Figure 1: Defining a research area in SciVal for ‘Rare Disease’ research.

There are many challenges faced by these
types of diseases, as they are often not
well defined or characterized. Rarity also
means that recruitment for trials is usually
quite difficult, study populations are widely
dispersed, and there are few expert centers
for diagnosis, management and research.
This is often accompanied by a lack of highquality evidence available to guide treatment.

At Research Trends we were curious to learn
more about the subject and to highlight some
of the key institutions and authors that are
contributing to the field of rare disease. To
do this we examined the field by looking at
publication trends using SciVal. To begin with
we created a research area in SciVal based
on the keyword search ‘rare disease’.

One of the reasons why this set of research
papers is small can be contributed to the
simplicity of the search terms used. In the
approach presented in this paper relevant
articles were selected on the basis of
the occurrence of the term ‘rare disease’
without including the names of the 7000
rare diseases themselves. We can therefore
assume that papers related to many rare
diseases would not be included in this set
as not all papers related to specific diseases
will include ‘rare disease’ in their abstract,
keywords or title. In a follow-up study we
could look into including search terms related
to particular rare diseases to provide a more
complete picture of this research field.

Institution

Country

Publications in
this Research
Area

Publications in
this Research
Area (growth %)

Citations

Authors

Citations per
Publication

Université Paris 5

France

77

23.1

740

11

9.6

INSERM

France

71

133.3

420

4

5.9

Harvard
University

United States

61

0

726

10

11.9

Université Paris 6

France

49

300

312

22

6.4

University of
Munich

Germany

45

42.9

206

3

4.6

Table 2: Most Prolific Institutions for ‘Rare Disease’ research in 2009-2013.
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Despite this small sample set, we took a look
at a number of institutions, and a number
of authors that were the most prolific in
this area. When looking at the three most
prolific institutions around the globe they
all originate from either France or the US,
bar one from Germany. Hence, this article
focuses on the two most prolific from both
countries, namely University Paris 5 and
Harvard, see Table 1 and Table 2.
Insitutional Collaboration maps for
Harvard, Paris 5 and Munich
Using SciVal we took a closer look at the
collaboration patterns of three individual
intitutions, Harvard University, Université
Paris 5 and University of Munich in ‘rare
disease’ research. SciVal allows you to drill
down from a worldwide, to a regional and
right down to a country level view of the
institutional collaborations.
As can be seen from Figure 2, Harvard
University collaborated with 171 institutions
worldwide on a total of 39 co-authored
publications of its total of 61 publications,
with the majority of the collaborations taking
place with authors within the US and Europe.
The average number of insitutions per paper
are 4,38. You can also see here that out of
the 61 articles 39 are co-authored with other
North American research organizations.
In fact, Harvard’s top 20 collaborating
institutions on ‘rare disease’ research
are mainly from the US, only three were
international cross-border collaborations,
namely with Canada, UK and Switzerland.
When one looks at the general collaboration
trends exhibited by Harvard they seem inline
with the trends exhibited within the area of
‘rare disease’ where the top collaborations
are all national institutions with few
international collaborating institutions from
abroad featuring in the top 40.
You can see from Figure 3 that Université
Paris 5 collaborated with 215 institutions
worldwide on 62 co-authored publications
out of its 77 total publications, resulting in an
average of 3,48 institutions involved in each
paper. From Figure 4 you can see that the
majority of collaborating institutions are from
France (72). In fact, there are only three nonFrench institutional collaborators amongst
their top 20 rare disease collaborators,
namely Canada, UK and Germany.

Figure 2: Worldwide collaboration by Harvard University in ‘Rare Disease’ research.

Figure 3: Worldwide collaboration Université Paris 5 in ‘Rare Disease’ research.

University

Single author
publications (%)

Institutional
collaboration
(%)

National
collaboration
(%)

International
collaboration
(%)

Harvard
University

9.6

20.8

31.1

38.5

Université
Paris 5

8.5

13.3

40.2

37.9

University of
Munich

8.1

24.1

20.7

47.1

Table 3: General collaboration trends for the three universities investigated.
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Here again in Figure 5 we find there are
a large number of institutions that work
on a number of papers, 73 institutions
collaborated on 18 articles, with an average
of 4 institutions per paper. The University
of Munich enters into the most crossboarder collaborations with half of its top
20 institutions coming from abroad, namely
three US, two UK, two Dutch, one Canadian
and one institute from the Czech Republic.
It seems logical for collaboration to play
a central role in ‘rare disease’ research,
though it may be expected that cross-border
collaborations would be most important
to effectively propel the research forward,
mainly due to the small patient numbers in
each country.

Figure 4: European collaboration by Université Paris 5 in ‘Rare Disease’ research.

The overal results show a large number of
institutions collaborting on one paper, and
it seems that Munich in general is a more
internationally focused research organization
from the three universitites investigated, see
Table 3 for the general collaboration trends
for these universities.
Highlighting the Most Prolific Authors
in SciVal
By looking at the most prolific authors in
the set, in addition to clicking though to
the abstracts in Scopus from SciVal, we
were able to get a better idea of the set of
research papers we were looking at.

Figure 5: Worldwide collaboration by University of Munich in ‘rare disease’ research.

Name

Publications in this
Research Area

Citations in this
Research Area

Citations per
Publication

Taruscio, D.

16

37

2.3

Simoens, S.

14

50

3.6

Groft, S.C.

11

53

4.8

The most prolific authors in the dataset
for ‘rare disease’ between 2009-2013
are: Dr. Domenica Taruscio, MD. Director
at the National Centre for Rare Diseases,
Instituto Superiore di Sanita, Rome, Italy;
Dr. Steven Simoens, Katholieke Universiteit
Leuven, Department of Pharmaceutical and
Pharmacological Sciences, Leuven, Belgium;
Dr. Stephen Groft, Director National Institutes
of Health, Office of Rare Disease Research
(see Table 4).

Table 4: Most Productive Authors in ‘Rare Disease’ research in 2009-2013.

https://www.researchtrends.com/researchtrends/vol1/iss36/7

4

Kisjes: Celebrating Rare Disease Day - A look into Rare Disease research

Research Trends Issue 36 March 2014

Dr. Domenica Taruscio MD. focuses her
research on setting systems in place that
can, firstly, help train and inform clinicians
to make the right diagnosis and secondly,
improve the dissemination of information
around symptomatic treatments. She has
just spent the last 30 months on a feasibility
study funded by the European Commission
(DG Sanco) addressing regulatory, ethical
and technical issues associated with the
registration of rare disease patients and
with the creation of an EU platform for
the collection of data on rare disease
patients and their communication among
qualified users.
Dr. Steven Simoens, on the other hand,
does not focus his research especially on
rare disease themselves. He works within
Pharmaceutical Sciences with a keen interest
in pharmaco-economics and ethics which
is where rare disease seem to come up in
his research. His publication rate is very
impressive with about 15 papers per year.
‘Rare disease’ research is a topic of concern
for this field of interest as there are debates
on the economic rationale behind society
supporting any part of the rare disease
value chain. There was a debate in the
Netherlands, for example, in 2012 related to
the cost of providing medication to patients
with Pompe’s disease. Medication for these
patients cost between 400-700,000 Euros
per patient per year. The economist Dr. Marc
Pomp introduced the concept of the qualityadjusted life year (QALY), where the costs
of medical treatment are placed in relation
to the quality of life in those years for the
patient. The level considered acceptable
was set at 50,000 Euro per year, far below
the cost of treating a Pompe patient, while
stopping their treatment would would most
likely cause them to die (1).

Published by Research Trends, 2007

The third most prolific researcher within
our sample, Dr. Stephen Groft, received the
life time achievement award for his nearly
30 years of service and commitment to
advancing research and treatments for
the millions of people afflicted by rare and
genetic diseases. He is one of the original
pioneers in the rare disease arena and is
recognized globally as a leader in building
collaborative relationships to improve patient
treatment and care. Pham. D. Groft retired
on February 8th this year. He was praised
for giving thousands of rare disease patients
and their families renewed hope and a
collective voice. One of the organizations he
set up was the National Center for Advancing
Translational Science (NCATS). You can read
more about his work at: http://www.ncats.
nih.gov/news-and-events/features/groft.html
Each of these three individuals look at rare
disease in very different ways, though all are
in some way interested in the management
of the research field, suggesting that
our keyword search did in fact omit the
research of ‘rare disease’ from the sample
set. However, this also shows how much
attention needs to be placed on attracting
the public’s attention for ‘rare disease’ and on
building global awareness and a collective
solidarity to support the population and their
families affected by these rare and often
severe diseases.
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The next International Conferences
for Rare Diseases and Orphan Drugs
(ICORD) 2014 Annual Meeting on October
8-10, 2014 in The Netherlands. More
information will follow: http://icord.se
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